Member Info for BertieBassett

Yes - 12/09/2023, 09:54 - two years!

-- BB --

Bravo

-- BB --

Well, Free Association Books has its formal address in Zug - which is between Lucerne and Zurich ... it's renowned for its production of kirsch ... which is tasty and highly addictive ...

Will get up to 31 degrees this weekend! Lucky Zug!

I note that TB's LinkedIn still reads CEO - IQ-AI ... https://www.xxxxxx.com/in/trevor-edward-brown-92548053/?originalSubdomain=ch

I wonder if he realises that the company has changed its name?!

ha!

-- BB --

If we get to 5p, I am out!!

-- BB --

I wonder how low this can now go ...

-- BB --

Onceaday ...

Didn't we recently endure a fundraise that approximately equates to the cost of submission?

Will we need ANOTHER one to meet any extra costs?

More questions ... answers Sematic?

-- BB --

It's interesting how TB likened IQAI/IBAI to Apple ... but Jobs and Cook engaged with shareholders ... during times of good and bad ...

Now is the time for Brown to be a Jobs or a Cook rather than a Zaslav or a Johnson

-- BB --

And all this selling of recent days ...

-- BB --

Sadly, Tyke .. I am unsure that the markets will take it that way ..

-- BB --

IBAI needs a "completion of an expanded data analysis would strengthen the submission and facilitate review."

"Imaging Biometrics anticipates resubmitting the BTD application as part of its broader regulatory and clinical strategy. "

Hmmm ...

-- BB --

Imaging Biometrics, Ltd, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, today announces that following recent dialogue with the U.S. Food and Drug Administration (FDA), the Company was encouraged to voluntarily withdraw and resubmit its Breakthrough Therapy Designation (BTD) application for oral gallium maltolate (GaM), an investigational treatment targeting refractory brain tumors.

The FDA's recommendation stems from a shared recognition of the potential impact of the agent and a mutual desire to ensure the application reflects the most compelling and mature data. The agency expressed enthusiasm for preliminary findings and suggested that resubmission after completion of an expanded data analysis would strengthen the submission and facilitate review.

"We view this feedback as an encouraging step forward," said Trevor Brown, CEO of Imaging Biometrics Ltd. "We believe the FDA's interest reinforces the scientific rationale behind GaM and supports our mission to accelerate new treatment options for patients facing devastating brain tumors. We are diligently working to incorporate additional biomarker and imaging efficacy data that will provide a more comprehensive picture of its therapeutic potential."

Imaging Biometrics anticipates resubmitting the BTD application as part of its broader regulatory and clinical strategy. The Company remains committed to the advancement of innovative technologies that intersect imaging intelligence with novel therapeutics to improve outcomes in neuro-oncology.

Tyke,

"same sh*t, different name"- moniker concocted in relation to Iosif Vissarionovich Dzhugashvili – known to you and me as Stalin (man of steel). Changed his name but not his ideology ...

BUT

we have to remember that the only useful members of the IBAI Team, KS, Musella etc (the IB Team - who we trust) are still there ... so some hope!

-- BB --

I suppose that if IB gets an offer, shares in BRH will zoom ...

Hedging ones bets I presume!

-- BB --

Up 3.13% on a name change!

Maybe IB should do this on a weekly basis.

In one year we would be laughing ... well, at least not crying!

BackRub became Google, Cadabra became Amazon ... let's hope IQ-AI is not a euphemism for Titanic.

-- BB --

No new information.

Usual one-sided manure.

BTW - "Disapplication of pre-emption rights" allows a company to issue new shares without first offering them to existing shareholders.

-- BB --

Tyke,

I do believe that that's what Musella is there for.

TB would be laughed out of the room ... but not Musella ... or the Drs C ...

So, keep the faith ... just!

-- BB --

Yes – a total latrine here, Paladin. As with our poor brethren in BRH.

HOWEVER – a) change of name b) FDA – 40 days to go c) interview with Dr C last week that "indicates" a clear route to Phase 2 d) Musella ...

We have hope ... a slight shaft of light ... but hope nonetheless ...

How is IB going to fund the next round? Fundraise? No. BRH? No. JV/buyout? Well ... let's hope. At this stage, 5 pence per share would be "result".

As Dodie Smith once wrote .. "wait and see" ...

Oh, I see an advert for Euromillions £140m tonight! May buy a ticket ... more chance of winning than seeing an ROI here!

-- BB --

Goolies for BRH.

We went through that over in IQAI a couple of weeks ago.

Our raise was to fund a FDA application - although we weren't advised of this ... of course.

Yours may be to pay for TB's salary or HOPEFULLY for something more substantive .

Hopefully you will receive another RNS next week

-- BB __

SO - we should hear something by July 1st.

I do believe that with the likes of Al Musella onboard, IB stands an infinitely better chance of it being granted - or at worst amended.

Note, Al Musella is - according to an IQ-AI RNS - "Non-Execuitve Director" ... shame IQ-AI didn't bother to use spellcheck ...

-- BB --

It's a GREAT move to (re) name the company "officially" IB ... and lose the IQAI. IQ has been battered and beaten by its awful reputation as a mismanaged and mistrusted entity.

IB has a fabulous reputation ... and I just hope that it is not tarnished in the future by the IQ board - as that would be a total disaster.

In IB I trust - in IQAI - well ....

-- BB --